Hakosil-D 8 Capsule is a combination pharmaceutical formulation containing Silodosin 8 mg and Dutasteride 0.5 mg, indicated for the management of benign prostatic hyperplasia (BPH). Silodosin, an alpha-1 adrenergic receptor antagonist, selectively relaxes the smooth muscle in the bladder neck and prostate, thereby improving urinary flow and reducing symptoms of urinary obstruction. Dutasteride, a 5-alpha-reductase inhibitor, decreases the conversion of testosterone to dihydrotestosterone (DHT), a hormone responsible for prostate enlargement, leading to a reduction in prostate volume over time. The synergistic action of these agents provides both immediate symptomatic relief and long-term reduction in prostate size, improving overall urinary function. Hakosil-D 8 Capsule is typically prescribed for men with moderate to severe BPH symptoms and an enlarged prostate. It is important to administer this medication under medical supervision, as it may cause side effects such as dizziness, hypotension, ejaculation disorders, and potential sexual dysfunction. Regular monitoring of prostate-specific antigen (PSA) levels is recommended during treatment to assess therapeutic response and detect any prostate malignancy. Patients should inform their healthcare provider of any history of liver disease, hypotension, or hypersensitivity to the components before initiating therapy.